MicroRNA-122–Mediated Liver Detargeting Enhances the Tissue Specificity of Cardiac Genome Editing
Brief intro:
- Author: Luzi Yang, Gonglie Chen, Congting Guo, Qinghua Cui, Xiaomin Hu, Yifei Li, Liang Chen, William T. Pu and Yuxuan Guo
- Journal: Circulation
- Publication Date: 2024 May 28
Abstract
Recombinant adeno-associated virus(rAAV) is broadly applied in cardiovascular research and gene therapy: Although AAV serotype 9 (AAV9) robustly transduces the liver, the heart, and other organs, its gene expression can be targeted to cardiomyocytes using a specific promoter usually from the cardiac troponin T gene (Tnnt2/cTnT). This AAv9-Tnnt2 system is heavily used in research, but its cardiac specificity relative to other organs requires greater investigation. This issue is especially important for applications where low or transient gene expression is sufficient to cause profound biological outcomes.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
